RRM2 and glioma: Previous attempts to target these genes have resulted in decreased viability and tumor initiating capacity of glioma cells [RRM2 (36)], induction of autophagic glioma cell death [UBE2C (39)], promotion of apoptosis, inhibition of cellular proliferation [HOXC10 (31)], and decreased tumor invasion [HOXC10 (31), SIM2 (34)].